Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier.
We produced low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as a carrier for heparin-binding growth factors, such as fibroblast growth factor-2 (FGF-2). A mixture of low-molecular-weight heparin (MW: about 5000 Da, 6.4 mg/mL) and protamine (MW: about 3000 Da, 10 mg/mL) at a ratio of 7:3 (vol:vol) yields a dispersion of microparticles (1-6 microm in diameter). In this study, diluted low-molecular-weight heparin solution in saline (0.32 mg/mL) mixed with diluted protamine (0.5 mg/mL) at a ratio at 7:3 (vol:vol) resulted in soluble nanoparticles (112.5 +/- 46.1 nm in diameter). The generated NPs could be then stabilized by adding 2 mg/mL dextran (MW: 178-217 kDa) and remained soluble after lyophilization of dialyzed LMW-H/P NP solution. We then evaluated the capacity of LMW-H/P NPs to protect activity of FGF-2. Interaction between FGF-2 and LMW-H/P NPs substantially prolonged the biological half-life of FGF-2. Furthermore, FGF-2 molecules were protected from inactivation by heat and proteolysis in the presence of LMW-H/P NPs.
Mori
Yasutaka
Y
Research Institute, National Defense Medical College, Tokorozawa, Saitama, Japan.
Nakamura
Shingo
S
Kishimoto
Satoko
S
Kawakami
Mitsuyuki
M
Suzuki
Satoshi
S
Matsui
Takemi
T
Ishihara
Masayuki
M
D002478:Cells, Cultured; D003460:Crystallization / Q000379:methods; D004058:Diffusion; D004337:Drug Carriers / Q000008:administration & dosage / Q000138:chemical synthesis*; D004339:Drug Compounding / Q000379:methods; D042783:Endothelial Cells / Q000378:metabolism*; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000737:chemistry*; D006801:Humans; D046911:Macromolecular Substances / Q000737:chemistry; D008422:Materials Testing; D008657:Metabolic Clearance Rate; D008968:Molecular Conformation; D050997:Nanomedicine / Q000379:methods; D049329:Nanostructures / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D011479:Protamines / Q000008:administration & dosage / Q000737:chemistry*; D013499:Surface Properties
D004337:Drug Carriers; D006495:Heparin, Low-Molecular-Weight; D046911:Macromolecular Substances; D011479:Protamines; D016222:Fibroblast Growth Factor 2
Biomaterials. 2005 Jun;26(16):3277-84
15603823
Thromb Haemost. 1995 Mar;73(3):439-43
7667826
Biomaterials. 2004 Feb;25(4):699-706
14607508
Int J Pharm. 2003 Jun 4;258(1-2):141-51
12753761
J Biochem. 2009 Mar;145(3):275-8
19074504
J Biomed Mater Res A. 2009 Dec;91(3):814-23
19051304
J Biomed Mater Res A. 2006 Aug;78(2):364-71
16673389
Glycobiology. 1999 Jul;9(7):705-11
10362840
Chest. 2001 Jan;119(1 Suppl):64S-94S
11157643
FASEB J. 1996 Sep;10(11):1270-9
8836040
Am J Cardiol. 1997 Nov 15;80(10):1336-8
9388109
Environ Health Perspect. 2003 Jul;111(9):1202-8
12842774
J Cell Physiol. 1986 Sep;128(3):475-84
3528177
Thromb Res. 1994 Jul 1;75(1):1-32
8073404
J Biomed Mater Res A. 2008 Jun 1;85(3):619-27
17806115